WebMD Chief Medical Officer John Whyte, MD, MPH, speaks with Elcin Barker Ergun, CEO of the Menarini Group, in Florence, Italy, about what they believe to be a new renaissance in healthcare.
Patients who underwent plasma ctDNA testing started therapy for advanced NSCLC earlier than those who underwent only tissue biopsy, but "plasma first does not mean plasma only," the authors say.